Intellia Therapeutics provides strategic update, cash ~$1.0B, workforce reduction of ~15%

Intellia Therapeutics, Inc.

Cash, cash equivalents and marketable securities ~$1.0B as of Dec 31, 2023; expected to fund operations into mid-2026.
Workforce reduction of approximately 15% and pause of select exploratory research-stage programs to focus on key priorities.
Initiated pivotal Phase 3 MAGNITUDE trial of NTLA-2001 for ATTR amyloidosis with cardiomyopathy; first patient dosing expected Q1 2024.
Completed enrollment and dosing in Phase 2 portion of NTLA-2002 study for hereditary angioedema; Phase 3 initiation planned 2H 2024.
Board member John Crowley departed in December following his appointment as CEO of BIO.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Intellia Therapeutics, Inc. reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023.

Period: the fourth quarter and fiscal year ended December 31, 2023
Result: preliminary results

Exact text from the filing

Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2023, Intellia Therapeutics, Inc. (the “Company”) announced on January 4, 2024, that it expects to report that it had approximately $1.0 billion of cash, cash equivalents and marketable securities as of December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-002438

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.